The present disclosure relates to methods of treating, preventing or ameliorating a TH17- or CSF1-mediated disease or disorder such as cancer, immunological disorders, and obesity by administering to a patient in need thereof a therapeutically effective amount of a FASN inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.本發明係關於治療、預防或改善TH17-或CSF1介導之疾病或病症(例如癌症、免疫病症及肥胖症)之方法,其係藉由向有需要之患者投與治療有效量之FASN抑制劑或其醫藥上可接受之鹽、水合物、溶劑合物、前藥、立體異構物或互變異構物達成。